Screening y selección de pacientes candidatos a un tratamiento frente al vhc en usuarios de drogas
Soledad López Calvo
Médico Adjunto del Servicio de Medicina Interna B. Complejo Hospitalario Universitario A Coruña (Antiguo Juan Canalejo) As Xubias de Arriba 84, 15006. La Coruña
Bibliografía
Brunt, EM. (2003). Grading and staging the
histopathological lesions of chronic hepatitis:
the Knodell histology activity index and beyond. 241-6.
Cales, P., Oberti, F., Michalak, S. HubertFouchard,I.,Rousselet, MC.,Konaté,A.,Gallois,
Y.,Ternisien,C.,Chevailler,A.,Lunel,F. (2005).A
novel panel of blood markers to assess the
degree of liver fbrosis. 1373-81.
Carrión, J.A., Colmenero, J., Bataller, R., Forns, X. (2007). Diagnóstico no invasivo de la
fbrosis hepática. 106-112.
Di Bisceglie, A. (1998). Hepatitis C. 351-55.
Erensoy, S. (2001). Diagnosis of hepatitis C
virus (HCV) infection and laboratory monitoring of its therapy. J. 271-81.
Hadziyannis, SJ., Sette, H. Jr, Morgan, TR.,
Balan, V., Diago, M., Marcellin, P., Ramadori,
G., Bodenheimer, H. Jr, Bernstein, D., Rizzetto,
M., Zeuzem, S., Pockros, PJ., Lin, A., Ackrill,
AM.; PEGASYS International Study Group
(2004). Peginterferon-alpha2a and ribavirin
combination therapy in chronic hepatitis C: a
randomized study of treatment duration and
ribavirin dose. 346-55.
Inglesby, TV., Rai, R.,Astemborski, J., Gruskin,
L., Nelson, KE.,Vlahov, D.,Thomas, DL. (1999).
A prospective, community-based evaluation
of liver enzymes in individuals with hepatitis
C after drug use. 590-96.
Kettaneh, A., Marcellin, P., Douvin, C.,
Poupon, R., Ziol, M., Beaugrand, M., de Lé-
dinghen,V. (2007). Features associated with
success rate and performance of FibroScan
measurements for the diagnosis of cirrhosis
in HCV patients: A prospective study of 935
patients. 628-34.
López Calvo, S., Castro Iglesias, A., Vázquez
Rodríguez, P., Pedreira Andrade, JD. (2008).
. Badalona, E.U.R.O.M.E.D.I.C.E., Ediciones
Médicas, S.L.
National Institutes of Health Consensus
Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002.
(2002). 3-20.
Orland, JR., Wright, TL., Cooper, S. (2001).
Acute Hepatitis C. 321-27.
Patel, K., Gordon, S.C., Jacobson, I., Hézode,
C.,Oh,E.,Smith, KM.,Pawlotsky, JM.,McHutchison, JG. (2004). Evaluation of a panel of noninvasive serum markers to differentiate mild
from moderate-to-advanced liver fbrosis in
chronic hepatitis C patients. 935-42.
Poynard, T., Bedossa, P., Opolon, P., de los
grupos OBSVIRC, METAVIR, CLINIYIR Y DOSVIRC. (1997). Natural history of liver
fbrosis progression in patients with chronichistopathological lesions of chronic hepatitis:
the Knodell histology activity index and beyond. 241-6.
Cales, P., Oberti, F., Michalak, S. HubertFouchard,I.,Rousselet, MC.,Konaté,A.,Gallois,
Y.,Ternisien,C.,Chevailler,A.,Lunel,F. (2005).A
novel panel of blood markers to assess the
degree of liver fbrosis. 1373-81.
Carrión, J.A., Colmenero, J., Bataller, R., Forns, X. (2007). Diagnóstico no invasivo de la
fbrosis hepática. 106-112.
Di Bisceglie, A. (1998). Hepatitis C. 351-55.
Erensoy, S. (2001). Diagnosis of hepatitis C
virus (HCV) infection and laboratory monitoring of its therapy. J. 271-81.
Hadziyannis, SJ., Sette, H. Jr, Morgan, TR.,
Balan, V., Diago, M., Marcellin, P., Ramadori,
G., Bodenheimer, H. Jr, Bernstein, D., Rizzetto,
M., Zeuzem, S., Pockros, PJ., Lin, A., Ackrill,
AM.; PEGASYS International Study Group
(2004). Peginterferon-alpha2a and ribavirin
combination therapy in chronic hepatitis C: a
randomized study of treatment duration and
ribavirin dose. 346-55.
Inglesby, TV., Rai, R.,Astemborski, J., Gruskin,
L., Nelson, KE.,Vlahov, D.,Thomas, DL. (1999).
A prospective, community-based evaluation
of liver enzymes in individuals with hepatitis
C after drug use. 590-96.
Kettaneh, A., Marcellin, P., Douvin, C.,
Poupon, R., Ziol, M., Beaugrand, M., de Lé-
dinghen,V. (2007). Features associated with
success rate and performance of FibroScan
measurements for the diagnosis of cirrhosis
in HCV patients: A prospective study of 935
patients. 628-34.
López Calvo, S., Castro Iglesias, A., Vázquez
Rodríguez, P., Pedreira Andrade, JD. (2008).
. Badalona, E.U.R.O.M.E.D.I.C.E., Ediciones
Médicas, S.L.
National Institutes of Health Consensus
Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002.
(2002). 3-20.
Orland, JR., Wright, TL., Cooper, S. (2001).
Acute Hepatitis C. 321-27.
Patel, K., Gordon, S.C., Jacobson, I., Hézode,
C.,Oh,E.,Smith, KM.,Pawlotsky, JM.,McHutchison, JG. (2004). Evaluation of a panel of noninvasive serum markers to differentiate mild
from moderate-to-advanced liver fbrosis in
chronic hepatitis C patients. 935-42.
Poynard, T., Bedossa, P., Opolon, P., de los
grupos OBSVIRC, METAVIR, CLINIYIR Y DOSVIRC. (1997). Natural history of liver
hepatitis C. 825-32.
Rockey, DC., Bissell, D.M. (2006). Noninvasive measures of liver fbrosis. 113-120.
Sandrin, L., Fourquet, B., Hasquenoph, JM.,
Yon, S., Fournier, C., Mal, F., Christidis, C., Ziol,
M., Poulet, B., Kazemi, F., Beaugrand, M., Palau,
R. (2003). Transient elastography: a new noninvasive method for assessment of hepatic
fbrosis. 1705-13.
Shakil, AO., Conry-Cantinela, C., Alter, HJ.,
Hayashi,P.,Kleiner, DE.,Tedeschi,V.,Krawczynski,
K.,Conjeevaram, HS.,Sallie,R.,Di Bisceglie, AM.
(1995). Volunteer blood donors with antibody
to hepatitis C virus: clinical, biochemical, virologic and hitologic features. 330-37.
Strader, DB., Wright, T., Thomas, DL., Seef, LB.,
American Association for the Study of Liver
Diseases. (2004). Diagnosis, Management, and
Treatment of Hepatitis C. 1147-71. Thorpe,
LE., Ouellet, LJ., Hershow, R., Bailey, SL.,Williams, IT.,Williamson, J, Monterroso, ER., Garfein,
RS. (2002). Risk of hepatitis C virus infection
among young adult injection drug users who
share injection equipment. 645-53.
Van Ameijdem, EJ., Van den Hoek, JA., Mientjes, GH., Continho, RA. (1993). A longitudinal
study of the incidence and transmission patterns of HIV, HBV and HCV infection among
drug users in Amsterdam. 255-62
Villano, SA., Vlahov, D., Nelson, KE., Lyles,
CM., Cohn, S., Thomas, DL. (1997). Incidence
and risk factors for hepatitis C among injection
drug users in Baltimore, Maryland. 3274-7.
Wiese, M., Berr, F., Lafrenz, M., Porst, H.,
Oesen, U. (2000). Low frecuency of cirrosis
in a hepatitis C (genotype 1b) single-source
outbreak in Germany: a 20 year multicenter
study. 91-6.
Asóciese ahora: www.aesed.com/suscripcion.php #drogas #adicciones
No hay comentarios:
Publicar un comentario